Share this article
Share this article
ABBOTT PARK, Ill., March 31, 2021 /PRNewswire/ Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter, non-prescription, asymptomatic use of its BinaxNOW™ COVID-19 Ag Self Test for detection of COVID-19 infection. This new indication allows individuals with or without symptoms to have access to this test without a prescription. Abbott will begin shipping to major food, drug and mass merchandiser retailers in the coming weeks and expect the test to be available through some of their online store websites.
A mother swabs her son’s nostril using a shallow nasal swab before conducting an Abbott BinaxNOW™ COVID-19 Self Test. The test will be available over-the-counter at major U.S. retailers and does not require a prescription. (PRNewsfoto/Abbott)
Share this article
Share this article
WOONSOCKET, R.I., April 1, 2021 /PRNewswire/ CVS Health (NYSE: CVS) has surpassed 10 million COVID-19 vaccine doses administered through its participation in the Pharmacy Partnership for Long-Term Care Program and Federal Retail Pharmacy Program. The company is now administering vaccines in nearly 2,000 stores across 44 states, Puerto Rico, and Washington, D.C., with the pace of vaccinations expected to rapidly accelerate as more supply becomes available. CVS Pharmacy has the capacity to administer up to 25 million shots per month. We ve experienced some of our highest customer satisfaction scores ever, which speaks to the seamless digital scheduling experience we ve built and the professionalism of our health care teams putting shots in arms, said Karen S. Lynch, President and Chief Executive Officer, CVS Health. We re working hard to help America fight COVID-19 by breaking down barriers to equitable health care, especially in communiti
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
News provided by
Share this article
Share this article
ATLANTA, April 1, 2021 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson s disease (PD) and related disorders inside and outside of the brain, today reported financial results for the fourth quarter and full year ended December 31, 2020 and highlighted recent developments.
Key Business and Clinical Highlights
Completed Initial Public Offering: In December 2020, Inhibikase successfully completed its initial public offering (IPO) of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The Company received aggregate net proceeds of approximately $14.60 million after deducting offering costs, underwriting discounts and commissions.
Arizona State Physicians Association (ASPA) Announces Partnership with PayGround
Healthcare payments aggregator, PayGround, partners with Arizona State Physicians Association to allow more than 1M patients to easily submit payments to nearly 3,000 ASPA providers.
News provided by
Share this article
Share this article
GILBERT, Ariz., April 1, 2021 /PRNewswire/ PayGround Inc., a healthcare payments firm outside of Phoenix, Ariz. announced today they have partnered with Arizona State Physicians Association (ASPA) to expand PayGround s payments platform across ASPA s network. ASPA represents the largest Independent Physician Association (IPA) in the Arizona market, with nearly 3,000 providers who have access to treating more than 1 million patients. With the partnership, patients in the ASPA network will be able to aggregate their bills and easily submit payments to their providers. This partnership not only supports ASPA patient s interests, but benefits ASPA s providers as well
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.2% from 2021 to 2026.
Growth in this market is driven by the increasing government funding for research, high prevalence of diseases, and growing focus on personalized medicine.
Consumables segment to witness the highest growth during the forecast period.
Based on the product, the cell lysis market is segmented into consumables and instruments. The consumables segment is projected to grow at the highest CAGR during the forecast period. purchase and high consumption, the high prevalence of diseases, and increasing funding for cell-based research are the major factors supporting the growth of this segment.